Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines

Martin K. Hunn, Ian F. Hermans

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigenpresenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications.

Original languageEnglish
Article numbere23789
Number of pages3
JournalOncoImmunology
Volume2
Issue number4
DOIs
Publication statusPublished - 1 Apr 2013
Externally publishedYes

Keywords

  • α-galactosylceramide
  • Cancer vaccine
  • Dendritic cell
  • Glioblastoma multiforme
  • Glioma
  • NKT cell

Cite this